Victory Capital Management
CTKB icon

Victory Capital Management’s Cytek Biosciences CTKB Stock Holding History

Victory Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77K Sell
17,621
-7
-0% -$33 ﹤0.01% 2288
2025
Q4 		$89K Sell
17,628
-2,805
-14% -$13K ﹤0.01% 2281
2025
Q3 		$70.9K Sell
20,433
-852
-4% -$3.2K ﹤0.01% 2321
2025
Q2 		$72.4K Sell
21,285
-329
-2% -$1.1K ﹤0.01% 2357
2025
Q1 		$86.7K Sell
21,614
-439
-2% -$2.27K ﹤0.01% 2323
2024
Q4 		$143K Sell
22,053
-692
-3% -$4.12K ﹤0.01% 2289
2024
Q3 		$126K Sell
22,745
-255
-1% -$1.45K ﹤0.01% 2293
2024
Q2 		$128K Buy
23,000
+835
+4% +$5.01K ﹤0.01% 2265
2024
Q1 		$149K Buy
22,165
+607
+3% +$4.8K ﹤0.01% 2257
2023
Q4 		$197K Sell
21,558
-7,820
-27% -$49.2K ﹤0.01% 2239
2023
Q3 		$162K Sell
29,378
-3,497
-11% -$28.1K ﹤0.01% 2234
2023
Q2 		$281K Buy
32,875
+4,161
+14% +$37.3K ﹤0.01% 2130
2023
Q1 		$264K Buy
+28,714
New +$309K ﹤0.01% 2179
2022
Q3 		– Sell
-10,379
Closed -$111K – 2713
2022
Q2 		$111K Sell
10,379
-26
-0.2% -$259 ﹤0.01% 2451
2022
Q1 		$98K Sell
10,405
-295
-3% -$3.98K ﹤0.01% 2515
2021
Q4 		$175K Buy
+10,700
New +$224K ﹤0.01% 2507

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Victory Capital Management's CTKB Position: Q1 2026 in Review

Victory Capital Management reduced its Cytek Biosciences (CTKB) stake by 0.04% in Q1 2026, selling an estimated $33 and leaving 17,621 shares worth $77K. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Victory Capital Management first reported a position in CTKB in Q4 2021 and has held it in 16 quarters since. The position peaked at $281K in Q2 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Victory Capital Management held 17,621 shares of Cytek Biosciences worth $77K as of Q1 2026.
  • Victory Capital Management sold 7 Cytek Biosciences shares in Q1 2026, an estimated $33.
  • Cytek Biosciences made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2288 holding.
  • Victory Capital Management first reported a position in Cytek Biosciences in Q4 2021 and has held it in 16 quarters since.
  • Victory Capital Management's Cytek Biosciences position peaked at $281K in Q2 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.